Here are five notes:
1. Cosentyx is the first in the interleukin-17A inhibitors class of medicine in Europe.
2. The medicine demonstrates sustained clinical benefits in ankylosing spondylitis and psoriatic arthritis. It doesn’t exhibit spinal damage in the majority of patients.
3. This medicine is the first development in 16 years for the treatment of ankylosing spondylitis.
4. About 9,600 patients have taken Cosentyx in clinical trials.
5. The medicine is licensed to treat ankylosing spondylitis in adults who saw no improvement with conventional therapy.
More articles on spine:
6 key notes on chronic opioid therapy for workers compensation spinal fusions
Rehabilitation gym focused on spinal cord injuries opens in Berkeley: 5 notes
Dr. Said Osman performs new endoscopic lamino-foraminoplasty surgery: 4 highlights
